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Abstract 
We describe here a spin-trapping method combined with X-band electron paramagnetic resonance (EPR) spectroscopy for ex vivo 
measurement of nitric oxide (. NO) levels in the urine of both normal and lipopolysaccharide (LPS)-induced shock mice. Normal or 
LPS-treated mice were injected subcutaneously with a metal-chelator complex, N-methyl-D-glucamine dithiocarbamate-ferrous iron, 
[(MGD)JFe], which binds to • NO and forms a water-soluble [(MGD)z/Fe-NO] complex. At 2 h after injection of the [(MGD)2/Fe] 
complex, a three-line EPR signal characteristic of the [(MGD)2/Fe-NO] complex was detected in the urine of either normal or 
LPS-treated mice. It is estimated that the concentrations of the [(MGD)2/Fe-NO] complex in normal and LPS-treated mouse urine were 
1.3 and 35 /xM, respectively. This 25-fold increase in • NO levels in the LPS-treated mouse urine provides the direct evidence that LPS 
challenge induces the overproduction f • NO in mice. Administration of N-monomethyl-L-arginine (NMMA; 50 mg/kg) inhibited the ex 
vivo signal intensities of the [(MGD)2/Fe-NO] complex in the urine of either normal or LPS-treated mouse urine. Furthermore, after 
injection of 15N-arginine (10 mg per mouse), a composite EPR spectrum, consisting of a three-line spectrum of the [(MGD)2/Fe-I4NO] 
complex and a two-line spectrum of the [(MGD)z/Fe-~SNO] complex, was detected in the urine. These isotopic tracer experiments 
further confirm that the detected .NO levels in the mouse urine are produced via the arginine-nitric oxide pathway. This ex vivo 
spin-trapping method should readily be adapted to experiments on larger animals and provide a noninvasive way of measuring both 
constitutive and inducible -NO synthase activities in living animals under physiological s well as pathophyiological onditions where 
• NO is overproduced. 
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1. Introduction 
Nitric oxide (. NO) is a free radical cell messenger that 
plays a pivotal role in numerous physiological and patho- 
logical functions [1-3]. Two major types of nitric oxide 
synthase, the constitutive and inducible enzymes, which 
utilize the guanidino nitrogen atom of L-arginine and in- 
corporate molecular oxygen to generate • NO and L-citrul- 
line, have been identified. The constitutive • NO synthase 
is present in the endothelium, where • NO is continuously 
generated at low concentrations to regulate the blood 
pressure and vascular tone. The inducible • NO synthase is 
present in many cell types including macrophages, neu- 
trophils, leukocytes, as well as hepatocytes, vascular en- 
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dothelial and smooth muscle cells. This • NO synthase is 
induced by lipopolysaccharide (LPS) and cytokines, and 
produces .NO at high concentrations for several days, 
which serves important roles in nonspecific immunity 
against inflammation and infection. In the case of severe 
infection, overproductions of • NO and cytokines can lead 
to septic shock, multiple organ failure and eventually death 
[4]. 
In blood, -NO produced by the endothelium diffuses 
isotropically through all directions into adjacent tissues. 
• NO diffusing into the vascular smooth muscle binds to 
guanylate cyclase enzyme, which catalyzes the production 
of cGMP, and induces vasodilatation [1-3]. On the other 
hand, • NO diffusing into the blood circulation reacts with 
hemoglobin in the red cell to yield nitrate and methemo- 
globin [5]. Nitrate is eliminated via renal excretion and 
methemoglobin is converted enzymatically into hemoglobin 
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by methemoglobin reductase in the red cell. It is therefore 
not surprising that serum nitrate levels are increased in 
cytokine-induced and septic shock in animals and humans 
[6-8]. 
Recently, we have shown that N-methyl-D-glucamine 
dithiocarbamate-ferrous iron, the [MGD/Fe] complex, is 
an excellent .NO spin-trapping reagent ~ [9,10]. Upon 
subcutaneous injection, the complex interacts with -NO 
produced in vivo in the LPS-treated mice, forming the 
stable and water-soluble [MGD/Fe-NO] complex, whose 
characteristic three-line spectrum present in the circulation 
of the tail of the conscious mouse can be detected by an 
S-band EPR spectroscopy [10]. Although this in vivo EPR 
spin-trapping method is sensitive for detecting micromolar 
• NO levels produced by the inducible form of • NO syn- 
thase enzyme, it is not sensitive enough for detecting 
nanomolar • NO levels produced by the constitutive •NO 
synthase. In the present study, we describe a spin-trapping 
method that is sensitive for ex vivo measurement of • NO 
levels produced by either constitutive or inducible • NO 
synthase nzyme activities in living animals. 
2. Materials and methods 
ICR mice (female, 20-30 g) were supplied by Harlan 
Sprague-Dawley (Indianapolis, IN). Dexamethasone, lipo- 
polysaccharide (LPS; E. coli 026:B6) and acetylcholine 
chloride were obtained from Sigma (St. Louis, MO). 15N 2- 
guanido-L-arginine (15y-arginine) was purchased from 
Cambridge Isotope Laboratories (Woburn, MA). N c- 
monomethyl-L-arginine (NMMA) was from Calbiochem 
(San Diego, CA). Methoxyflurane was obtained from Pit- 
man-Moore (Mundelein, IL). Pure • NO gas was purchased 
from Matheson (Joliet, IL) and pure argon gas was ob- 
tained from Airco (Murray Hill, NJ). Saturated •NO solu- 
tion in water was prepared by following the method of 
Kelm and Schrader [5]. The concentration of the saturated 
• NO solution is 2.0 mM, as verified by an ISO-NO meter 
from World Precision Instruments (Sarasota, FL). NO~ 
was measured by a colorimetric assay [11]. NO 3 was first 
converted to NO 2 by E. coli nitrate reductase [12] and 
measured as described above. N-Methyl-D-glucamine and 
carbon disulfide were obtained from Aldrich (Milwaukee, 
WI). N-Methyl-o-glucamine dithiocarbamate (MGD) was 
synthesized by following the method of Shinobu et al. [13]. 
Creatinine levels in the urine of control and the LPS-treated 
mice were measured by using Kodak-Ektacam/700 ana- 
lyzer (Eastman-Kodak, Rochester, NY). 
Conventionally, the term spin trapping refers to the use of nitrone or 
nitroso compounds that react with a reactive free radical to yield a stable 
spin adduct. In this report, his term is extended toinclude the stabiliza- 
tion of a reactive free radical through interactions with a metal-chelator 
complex without the formation ofa new covalent bond. 
2.1. EPR measurement of nitric oxide levels 
(i) In vivo measurement of [(MGD)2/Fe-NO] levels in 
the circulation of the LPS-treated mice. The noninvasive in 
vivo EPR spectra were recorded with an EPR spectrometer 
equipped with an S-band microwave bridge and a low- 
frequency loop-gap resonator with a 4-mm loop with a 
length of 1 cm, operating at 3.5 GHz [14]. Instrument 
settings include 100-G field scan, 30-s scan time, 0.l-s 
time constant, 2.5-G modulation amplitude, 100-KHz mod- 
ulation frequency and 25-mW microwave power. The mea- 
sured unloaded Q of the empty resonator was 3000 and the 
loaded Q was 400 (with the presence of the mouse tail). 
Other instrument settings and experimental conditions have 
been described previously [9,10]. For measurement of ~5 NO 
production, at 6 h after i.v. injection of LPS (6 mg/mouse) 
via the lateral tail vein, the mice were anesthetized with 
methoxyflurane prior to subcutaneous injections of 15N- 
arginine (5 or 10 mg per mouse) in saline, and of 0.4 ml of 
the [(MGD)JFe] complex (326 mg/kg  of MGD and 34 
mg/kg  of FeSO 4) in water; none of the LPS-treated mice 
survived over 24 h [10]. Immediately after injection, the 
mouse housed in a plexiglass restraining tube was trans- 
ferred to the S-band EPR spectrometer and the tail of the 
mouse was immobilized by taping down with a thin and 
narrow plexiglass stick and then placed inside the res- 
onator; no anesthetic agent was used. The in vivo EPR 
signal was recorded at 2 h after the injection of the 
[(MGD)2/Fe] complex. For inhibition experiments, at 6 h 
after LPS treatment, mice were injected intraperitoneally 
with an aliquot of 50 mg/kg  NMMA in saline, and at 1 
and 1.5 h prior to LPS challenge, mice were injected 
intravenously with 3 mg/kg  dexamethasone i  saline. The 
in vivo EPR signal was also recorded at 2 h after the 
injection of [(MGD)2/Fe] complex. The concentrations of
the [(MGD)2/Fe-NO] complex in the urine samples were 
calculated by comparing the signal intensities obtained 
from the samples to the signal intensity of a standard 
solution containing 0.1 mM of the [(MGD)2/Fe-NO] com- 
plex. 
(ii) Ex vivo measurements of [(MGD)2/Fe-NO] levels 
in the urine of normal mice. Normal mice housed in a 
restraining tube were injected subcutaneously with 0.4 ml 
of the [(MGD)2/Fe] complex. After 2 h, the animals were 
sacrificed and the urine samples were collected from the 
urinary bladder• The urine sample which was dark brown 
characteristic of the presence of [(MGD)2/Fe] complex 
was transferred to a quartz flat cell for EPR measurement. 
The spectra were recorded at 22°C with an X-band EPR 
spectrometer, operating at 9.5 GHz. Instrument settings 
include 100-G field scan, 4-min scan time, 0.5-s time 
constant, 2.5-G modulation amplitude, 100-KHz modula- 
tion frequency and 100-mW microwave power. For inhibi- 
tion experiments, mice were injected intraperitoneally with 
50 mg/kg  NMMA in saline immediately after the injec- 
tion of the [(MGD)2/Fe] complex• In other experiments, 
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mice were injected intravenously with 3 mg/kg dexa- 
methasone in saline about 1.5 h before the injection of the 
[(MGD)2/Fe] complex. For measurement of 15NO produc- 
tion in normal mice, mice were injected subcutaneously 
with 15N-arginine (5 or 10 mg/mouse) in saline immedi- 
ately before the injection of the [(MGD)2/Fe] complex. 
Acetylcholine chloride (Sigma) in saline was freshly pre- 
pared prior to subcutaneous injection at a dose of 67 
mg/kg. 
(iii) Ex vivo measurement of [(MGD)z/Fe-NO] levels 
in the urine of the LPS-treated mice. At 0, 2, 4, 6 or 8 h 
after LPS treatment (6 rag/mouse; at least three animals in 
each group), the mice housed in a restraining tube were 
anesthetized with methoxyflurane prior to subcutaneous 
injection with 0.4 ml of the [(MGD)2/Fe] complex. After 
2 h, the mouse was sacrificed and the urine sample was 
collected from the urinary bladder, and immediately trans- 
ferred to a quartz flat cell for X-band EPR measurement as 
described in Section 2. Inhibition experiments with NMMA 
or dexamethasone w re performed as described in Section 
2, except that the mice were treated with LPS prior to 
following the protocols for .NO inhibition experiments. 
The procedures for S-band EPR measurement of wet tis- 
sues and blood samples were as described previously [10]. 
3. Results 
o~ 
Fig. 1. Effects of .NO inhibitors on ex vivo 9.5-GHz EPR spectra of the 
[(MGD) 2/Fe-NO] complex detected in the urine of normal mice. The 
mice were injected subcutaneously with 0.4 ml of the [(MGD) 2/Fe] 
complex (A), and in the presence of NMMA (50 mg/kg)  (]3), or of 
dexamethasone (3 mg/kg)  (C). Details of the experimental protocols 
have been described in Section 2. The animals were sacrificed at 2 h after 
injections, and the urine samples collected were transferred to a quartz 
flat cell for EPR measurement at 22°C. The three-line spectrum of the 
[(MGD) 2/Fe-NO] complex is indicated by open circles (O), and a broad 
EPR line which is part of the spectrum of the [(MGD) 2/Cu]  complex is 
indicated by an arrow. 
3.1. Detection of the [(MGD)2/Fe-NO] complex in the 
urine of normal mice 
At 2 h after subcutaneous injection of an aliquot (0.4 
ml) of the [(MGD)2/Fe] complex (83.3 mM/16.7 mM) 
into normal mice, their urine samples were transferred into 
quartz flat cells for X-band (9.5 GHz) EPR measurement. 
The spectrum of the urine samples was found to be 
composed of two components, a three-line spectrum (open 
circles; a N = 12.5 G and gi~o --- 2.04) characteristic of the 
[(MGD)2/Fe-NO] complex, and a strong broad signal 
(indicated by an arrow) as shown in Fig. 1A. The strong 
broad signal is part of the EPR spectrum of the 
[(MGD)2/Cu] complex present in the urine, resulting from 
the chelation of urinary copper by the excreted MGD 
molecule (unpublished data). The significance of this find- 
ing is still not known. The concentration of the 
[(MGD)2/Fe-NO] complex detected in the urine sample 
was estimated to be 1.3 /~M (Table 1). Simultaneous 
injection of the [(MGD)z/Fe] complex and N-mono- 
methyl-L-arginine (NMMA; 50 mg/kg), an inhibitor of 
both constitutive and inducible synthase activities [15,16], 
reduced markedly the [(MGD)2/Fe-NO] signal in the urine 
sample as shown in Fig. 1B and Table 1. On the other 
hand, injection of the [(MGD)2/Fe] complex into mice 
pretreated with dexamethasone (3 mg/kg), an inhibitor of 
the inducible • NO synthase, but not the constitutive •NO 
synthase [17], produced negligible effects on the 
[(MGD)2/Fe-NO] signal (Fig. 1C and Table 1). The re- 
suits suggest hat the • NO detected in the normal mouse 
urine in the form of the [(MGD)2/Fe-NO] complex as 
shown in Fig. 1A was produced by the constitutive .NO 
synthase, but not by the inducible .NO synthase. To 
further verify this ascertain, we tested the effect of acetyl- 
choline, a vasodilatory agent which is known to effect the 
basal • NO level, but not the inducible • NO level [18-20], 
on the urinary [(MGD)2/Fe-NO] level of normal mice. 
Injection of acetylcholine was found to produce a 3-fold 
increase in the urinary [(MGD)2/Fe-NO] level (Table 1). 
This observation represents he first direct in vivo evidence 
to confirm that the endothelium-derived r laxation factor 
Table 1 
Quantitation of the amounts of the [(MGD) 2/Fe-NO] complex present in 
the mouse urine under various conditions 
Conditions [(MGD) 2/Fe-NO]. tzM ~ 
Controls 1.3 __+ 0.2 (8) b 
+NMMA (50 mg/kg)  0.4 :k 0.3 (8) * 
+ Acetylcholine (67 mg/kg)  3.9_+ 0.8 (3) * 
+ Dexamethasone (3 mg/kg)  1.4 + 0.3 (7) 
The amounts of the [(MGD) 2/Fe-NO] complex in the mouse urine 
were calculated by comparing the EPR signal intensities of the mouse 
urine with the signal intensity of a standard solution containing a known 
concentration of the [(MGD) 2/Fe-NOJ complex. 
6 The data presented are mean + S.E. (number of mice). 
* P < 0.05 compared with controls. 
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Fig. 2. Ex vivo 9.5-GHz EPR spectra of the [(MGD) 2/Fe-tSNO] and 
[(MGD)2/Fe-14NO] complexes present in the urine of normal mice 
injected with 15s-arginine. The mice were injected with 0.4 ml of the 
[(MGD)2/Fe] complex with (A) 10 mg 15N-arginine or (B) 5 mg 
15N-arginine. The animals were sacrificed at 2 h after injections, and the 
urine samples were transferred to a quartz flat cell for EPR measurement 
at 22°C. Note: The two-line spectrum of the [(MGD) 2/Fe-15NO] com- 
plex is indicated by close circles (Q). The dotted lines of the 
[(MGD) 2/Fe-14NO] spectrum in A as indicated by open circles (O) 
were obtained without he injection of 15N-arginine. The receiver gain for 
A was 1.3 times higher than that of B and the rest of the experimental 
conditions were the same as described in Fig. 1. 
released by acetylcholine (the Furchgott phenomenon) is 
indeed nitric oxide. 
It is now well characterized that L-arginine is converted 
into .NO and citrulline by .NO synthase nzymes [1-3]. 
To determine the origin of • NO detected in the normal 
mouse urine, we injected simultaneously 15N-arginine (10 
mg/mouse) and the [(MGD)2/Fe] complex, and measured 
the EPR signal in the urine sample as described above. Our 
rationale was that if the • NO detected in the normal mouse 
urine as shown in Fig. 1 comes from the arginine-NO 
synthase pathway, upon injection of 15t~-arginine, one 
should expect to detect the 15NO in the form of the 
[(MGD)2/Fe - 15 NO] complex in the urine. This indeed was 
the case as shown in Fig. 2A, in which the two-line 
spectrum of the [(MGD)2/Fe-15 NO] complex (close cir- 
cles) was detected in the urine, along with a weak three-line 
14 spectrum of the [(MGD)2/Fe- NO] complex (open cir- 
cles) in which the I aNO was  generated from the same 
enzymatic pathway, except utilizing endogenous 14N- 
arginine as a substrate. This suggests that the subcuta- 
neously injected ~sN-arginine competes effectively against 
endogenous t4N-arginine as a substrate for • NO synthases. 
When tsN-arginine was omitted from the injection solution, 
the typical three-line spectrum of the [(MGD)2/Fe-14 NO] 
complex became more visible (the dotted lines of Fig. 2A). 
On the other hand, when the amount of |sN-arginine 
injected (5 mg/mouse) was reduced by one-half, the 
signal intensity of the [(MGD)2/Fe-15 NO] complex was 
found to be decreased compared to that of the 
[(MGD)2/Fe-14 NO] complex (Fig. 2B; closed circles). 
Therefore, it can be concluded that the [(MGD)2/Fe] 
complex injected subcutaneously into the normal mice 
interacts with the .NO produced in tissues through argi- 
nine-constitutive -NO synthase pathway to form the 
[(MGD)2/Fe-NO] complex, which is eventually excreted 
and concentrated in the urine. 
3.2. Detection of the [(MGD)2/Fe-NO] complex in the 
blood circulation of LPS-treated mice 
We showed previously that upon bolus infusion of LPS 
(6 mg/mouse), mice were in septic-shock like conditions 
within 6 h as indicated by a gradual fall in mean arterial 
pressure from 121 +__ 3 mm Hg to 85 + 7 mm Hg, and that 
at 6 h after LPS treatment, the in vivo three-line spectrum 
of the [(MGD)JFe-NO] complex was observed in the 
circulation of the mouse tail as detected by S-band EPR 
spectroscopy [10]: The [(MGD)2/Fe] complex was in- 
jected subcutaneously 2 h before EPR measurement. To
further ascertain the chemical nature of • NO detected in 
LPS-treated mice, we injected 15N-arginine (10 mg/kg) 
together with the [(MGD)2/Fe] spin-trapping reagent into 
LPS-treated mice and measured the in vivo S-band EPR 
spectrum. Albeit weak, the in vivo two-line spectrum of 
the [(MGD)2/Fe-15 NO] complex in the circulation of the 
mouse tail was clearly visible (the solid lines of Fig. 3A), 
further confirming that the detected •NO in the form of the 
[(MGD)2/Fe-NO] complex in LPS-treated mice was pro- 
duced via the arginine-NO synthase pathway. The three-line 
spectrum of the [(MGD)2/Fe-14NO] complex in Fig. 3A 
o 
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Fig. 3. In vivo 3.5-GHz EPR spectra of the [(MGD) 2/Fe-NO] complex 
in the circulation of the mouse tail. At 6 h after LPS administration, the 
mice were injected with 10 mg of 15N-arginine in saline and 0.4 ml of the 
[(MGD) 2/Fe] complex. The in vivo S-band EPR spectra were recorded 2
h after the [(MGD) 2/Fe] administration (the solid lines). Note: spectral a
exhibits a characteristic two-line spectrum of the [(MGD) 2/Fe-15NO] 
complex (O). The dotted-line spectrum of the [(MGD)2/Fe-14NO] 
complex in (A) (C)) was obtained when 15r~-arginine was omitted from 
the above injection solutions. The ex vivo X-band EPR spectrum of the 
whole blood obtained from the 15N-arginine treated mice was shown in 
(B). The instrumental settings were as described in Section 2. 
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Fig. 4. Ex vivo 3.5-GHz EPR spectra of the [(MGD) 2/Fe-tSNO] and 
[(MGD) 2/Fe-]4NO] complexes detected in various tissues of the LPS- 
treated mice after intravenous injection of 15N-arginine. The experimental 
conditions were the same as described in Fig. 3. At 2 h after the 
[(MGD) 2/Fe] injection, the mice were sacrificed and wet tissues uch as 
(A) liver and (B) kidney were transferred to a quartz tubes (i.d. 2 mm) for 
EPR measurement at 22°C. Note: the two-line spectrum of the 
[(MGD) z/Fe-ISNO] complex (0) is superimposed with the three-line 
spectrum of the [(MGD)2/Fe-14NO] complex ((3) in A. The dotted 
three-line spectrum ofthe [(MGD) 2/Fe-NO] complex in A was obtained 
when ~SN-arginine was omitted from the injection solutions. Each spec- 
trum presented here was an average of nine 30-s scans. The receiver gain 
in (B) was twice of that in (A). 
(the dotted lines) was obtained when ~sN-arginine was 
omitted. The mice treated with ~sN-arginine were sacri- 
ficed, and the whole blood obtained was transferred for 
X-band EPR measurement a 22°C. Fig. 3B showed that 
the EPR signal of the whole blood obtained from tSN- 
arginine treated mice is identical to that of the solid lines 
of Fig. 3A. This suggests that the EPR signal in Fig. 3A or 
3B is attributed to the [(MGD)2/Fe-NO] complex circulat- 
ing in the blood rather than trapped in the tail muscle at or 
near the site of injection. 
The S-band EPR signal of the [(MGD)2/Fe-]SNO] 
complex was also detected in various isolated tissues 
obtained from LPS-treated mice injected with the 
[(MGD)2/Fe] complex and 15N-arginine as shown in Fig. 
4, in which the two-line [(MGD)2/Fe-15NO] spectrum 
(close circles) superimposed with the three-line 
[(MGD)z/Fe - 14 NO] spectrum (open circles) were found in 
the liver (Fig. 4A) and kidneys (Fig. 4B). Again, the dotted 
lines spectrum of the [(MGD)2/Fe-]4NO] complex de- 
tected in the mouse liver (Fig. 4A) was obtained when 
15N-arginine was omitted from the injection fluid. Kubrina 
et al. showed previously that upon simultaneous injection 
of diethyldithiocarbamate (DETC) as an • NO spin-trap- 
ping reagent and 15N-arginine into LPS-treated mice, an 
EPR spectrum of the [(DETC)2/Fe-15 NO] complex was 
detected in the isolated liver tissue at liquid nitrogen 
temperature [21]. 
3.3. Detection of the [(MGD)2/ Fe-NO] complex in the 
urine of LPS-treated mice 
Fig. 5A showed a strong three-line spectrum of the 
[(MGD)2/Fe-NO] complex detected in the urine sample 
obtained from the LPS-treated mouse injected with the 
[(MGD)2/Fe] complex. We estimated its concentration to 
be 35 /xM at 8 h after LPS challenge; the [(MGD)2/Fe] 
complex was injected at 6 h after LPS (Table 1). The 
time-dependent increase in [(MGD)2/Fe-NO] levels de- 
tected in urine samples after LPS administration was shown 
in Table 3, in which the [(MGD)2/Fe-NO] level in the 
urine was found to increase by 25-fold compared to that of 
controls at 8 h after LPS challenge. The reason why a 
plateau was reached between 4 and 6 h is not known 
(Table 3). Injection of NMMA reduced markedly the 
signal intensity (Fig. 5B) as well as the amounts of the 
[(MGD)2/Fe-NO] complex (Table 3), which is consistent 
with the notion that the • NO trapped by the [(MGD)2/Fe] 
complex injected in the LPS-treated mice is produced 
mainly by the inducible • NO synthase. Thus, the inducible 
• NO synthase activities in living animals may be assessed 
by noninvasively monitoring the elevated levels of the 
[(MGD)2/Fe-NO] complex present in the isolated urine 
with the use of EPR spectroscopy. 
One important question concerning this ex vivo spin- 
trapping method is whether the [(MGD)2/Fe-NO] complex 
detected in the urine was a result of the excretion of the 
circulatory [(MGD)2/Fe-NO] complex from the kidneys or 
a result of the reaction between the excreted [(MGD)2/Fe] 
complex and other chemicals present in the urine. To 
answer this question, we added the [(MGD)2/Fe] complex 
into the urine isolated from either normal or LPS-treated 
mice, and observed no detectable EPR signal of the 
Ji 
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Fig. 5. Effects of NMMA on ex vivo 9.5-GHz EPR spectra of the 
[(MGD) 2/Fe-NO] complex in the urine of the LPS-treated mice. At 6 h 
after LPS treatment, the mice were injected with the [(MGD) 2/Fe] 
complex and (A) without and (B) with i.p. injection of NMMA (50 
mg/kg). The mice were sacrificed at 2 h after injection of the 
[(MGD) 2/Fe] complex. The urine samples were collected and the EPR 
measurement was carried out at 22°C. The receiver gain was two times 
less compared tothat in Fig. 1. 
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[(MGD)2/Fe-NO] complex (data not shown), indicating 
that the detected [(MGD)2/Fe-NO] complex was not 
formed in the urine rather it was produced in tissues and 
excreted into the urine. 
The time-dependent i crease in plasma nitrate levels in 
LPS-treated mice was summarized in Table 2, in which 
nitrate levels were shown to increase with time after LPS 
challenge and the injection of the • NO trapping agent, 
[(MGD)2/Fe] complex, reduced the nitrate level in the 
plasma by about one-halL a result suggesting that the 
trapping of .NO by the [(MGD)2/Fe] complex in the 
LPS-treated mice prevents it from interactions with 
hemoglobin in the red cell, thereby reducing nitrate levels 
in the plasma. 
Furthermore, simultaneous injection of 15N-arginine (10 
mg/mouse) and the [(MGD)2/Fe] complex into the LPS- 
treated mice gave rise to a composite EPR spectrum, 
consisting of a two-line spectrum of the [(MGD)2/Fe- 
~sNO] complex (close circles), and a three-line spectrum of 
the [(MGD)2/Fe-laNO] complex (open circles) as shown 
in Fig. 6A (the solid lines). The pure three-line spectrum 
of the [(MGD)2/Fe-14 NO] complex as depicted by the 
15 - • dotted lines in Fig. 6A was obtained when N-arglnme 
was omitted from the injection solution. In addition, when 
lSN-arginine was administered at a level of 5 mg/mouse, 
the signal intensity of the [(MGD)2/Fe-15NO] complex 
was reduced compared to that of the [(MGD)2/Fe-14 NO] 
complex (Fig. 6B). The results clearly confirm that the 
• NO detected in the LPS-treated mouse urine was overpro- 
duced via the arginine-NO synthase pathway. One poten- 
tial problem which may affect the quantitation of the 
detected •NO levels is the variation of the urinary volume 
in mice, particularly as affected by the administration of 
NMMA, which has been shown to reduce urine output 
[23]. In fact, the amount of the urine collected in the 
Table 2 
Effects of LPS and the [(MGD) 2/Fe]  complex on total nitrate/nitrite 
levels in mouse plasma 
Conditions Nitrate/nitrite, izM a 
Controls 73 + 7 (10) a 
LPS-treated b
2 h 103 +__ 10 (6) * 
4 h 291 -t-38 (6) * 
6 h 506 + 75 (4) * 
8 h 638 + 29 (8) * 
LPS + [(MGD) 2/Fe] complex c 
8 h 336_+46 (3) ** 
a The nitrate/nitrite determination i  the mouse plasma was described in 
Section 2. 
b The mice were sacrificed at different time points as indicated after 
intravenous injection of LPS. 
c At 6 h after LPS challenge the mice were injected subcutaneously with 
the [(MGD) 2/Fe]  complex and were sacrificed 2 h later. 
d The data presented are mean + S.E. (number of mice). 
* P < 0.05 compared with controls 
t p < 0.05 compared with the LPS-treated group at 8 h. 
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Fig. 6. Ex vivo 9.5 GHz EPR spectra of the [(MGD)2/Fe-rSNO] and 
[(MGD) 2/Fe-~4NO] complexes in the urine of the LPS-treated mice 
injected with 35N-arginine. At 6 h after LPS treatment, he mice were 
injected with 0,4 ml of the [(MGD) 2/Fe]  complex and (A) in the 
presence of 10 mg I~N-arginine or (B) 5 mg 15N-arginine in saline. The 
urine samples collected at 2 h after injection of the [(MGD) 2/Fe] 
complex were transferred in quartz flat cells for EPR measurement at 
22°C. The solid lines in A show a composite of two spectra, namely, the 
two-line spectrum of the [(MGD)2/Fe-I-~NO] complex (0 )  and the 
three-line spectrum of the [(MGD) 2/Fe-14NO] complex (O). The dot- 
ted-three line spectrum of the [(MGD) 2/Fe-14NO] complex in A was 
obtained whentSN-arginine was omitted from the injections. The receiver 
gain in A was four times less than that in B. The microwave power was 
30 mW and the other instrumental settings were the same as described in 
Section 2. 
NMMA-treated mice was slightly reduced compared to the 
untreated mice. However, this should not affect the inter- 
pretation of the results presented in Fig. 1 and Table 1, 
because the signal intensity for the NMMA-treated mice as 
shown in Fig. 1B should be even weaker when corrected 
for the volume reduction. In addition, measurement of
creatinine levels showed that the creatinine levels in nor- 
mal and LPS-treated mouse urine were 5.1 + 0.4(3) and 
4.8 ___ 0.5(4) mM, respectively. Although the results pre- 
sented here show that LPS challenge does not influence 
the creatinine level, the possibility that it affects the urine 
flow rate, thereby changing the urine output, cannot be 
ruled out. 
4. Discussion 
Because it is relatively easy to collect the specimens, 
urine has been used as a diagnostic material in medicine 
for centuries [22]. In this study, we describe an EPR urine 
analysis employing the [(MGD)2/Fe] complex as a • NO 
spin-trap reagent to measure • NO levels produced in vivo 
in either normal or the LPS-treated mice. Basically, in this 
method, the spin-trapping reagent is injected into the mice 
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and after 2 h the urine is collected for EPR quantitation of 
the spin adduct levels• Utilizing this method, we found that 
the [(MGD)2/Fe-NO] levels in the normal and the LPS- 
treated mouse urine samples are 1.3 and 35 /xM, respec- 
tively (Table 1). The 25-fold increase in the -NO levels 
detected in the LPS-treated mouse urine is consistent with 
the notion that the intravenous injection of LPS from E. 
coli induces the expression of the inducible form of • NO 
synthase activities resulting in the overproduction of • NO. 
The in vivo [(MGD)2/Fe-NO] level in the circulation of 
the LPS-treated mice was estimated to be about 5 ~M 
(Fig. 3A). Therefore, the concentration of the 
[(MGD)2/Fe-NO] complex in the LPS-treated urine is 7 
times more than that found in blood. Extrapolating this 
concentration factor to normal mouse situations, we esti- 
mate that the • NO level in the normal mouse blood may 
be in the range of submicromolar levels• However, this 
estimated •NO levels may not reflect the true "free" • NO 
level present in blood -which is thought o be only a few 
nanomoles -rather the • NO that is trapped and stabilized 
by the spin-trap reagent in normal mice. Our recent low- 
temperature EPR investigations showed detectable .NO- 
hemoglobin at submicromolar levels in the whole blood of 
normal rats (unpublished ata), an observation that is 
consistent with our spin-trapping data reported here. 
Although the route by which the subcutaneously in- 
jected spin-trapping reagent enters the tissues before its 
excretion into the urine is not yet known, we speculate that 
upon subcutaneous injection, the [(MGD)2/Fe] complex 
diffuses across the capillary bed, where it interacts with 
• NO produced by -NO synthases to form the 
[(MGD)2/Fe-NO] complex. The latter complex then enters 
the blood circulation and is eventually excreted and con- 
centrated in the urine. The isolated urine containing the 
[(MGD)2/Fe-NO] complex was found to be stable at 4°C 
for several hours. When the [(MGD)z/Fe] complex was 
injected intravenously into normal or LPS-treated mice, the 
EPR signal of the [(MGD)2/Fe-NO] complex was also 
detected in the urine (data not shown). This suggests that 
regardless of its route of administration, the [(MGD)2/Fe] 
complex is capable of interacting with the -NO produced 
in vivo to form the [(MGD)2/Fe-NO] complex. 
The question is raised whether the .NO detected in 
normal mouse urine (Fig. 1) is a result of the injection of 
the [(MGD)z/Fe] complex. In other words, does the injec- 
tion of the complex alone enhance the • NO production in 
vivo? In our previous experiments, we showed that the 
intravenous injection of the [(MGD)2/Fe] complex did not 
affect the mean arterial pressure of mice [9], suggesting 
that the complex by itself does not seem to affect the in 
vivo • NO production. 
Experiments using • NO inhibitors showed that NMMA, 
an inhibitor of both constitutive and inducible forms of 
• NO synthase, at a level of 50 mg/kg  inhibited effectively 
both the • NO production in the normal mouse urine (Fig. 
1) as well as in the LPS-treated mouse urine (Fig. 5 and 
Table 3 
Time-dependent changes in the amounts of the [(MGD) 2/Fe-NO] com- 
plex present in the LPS-treated mouse urine 
Conditions [(MGD) 2/Fe-NO], /xM ~ 
LPS-treated b 
0 h 1.4_ 0.4 (3) c 
2 h 7.3 + 2.2 (3) 
4 h 18.2+4.8 (4) * 
6 h 17.1 +4.8 (4) ~ 
8 h 35.1 -+ 5.7 (3) * 
LPS-treated (after 6 h) d 
+ NMMA (50 mg/kg) 3.6 5:0.9 (4) + 
+NMMA (100 mg/kg) 3.8-+2.3 (3) + 
" The amounts of the [(MGD) 2/Fe-NO] complex in the mouse urine 
were determined as described in Table 1. 
b At different ime points after LPS challenge as indicated, the mice were 
injected subcutaneously with the [(MGD) 2/Fe] complex, and were sacri- 
ficed 2 h later to collect the urine for EPR measurement. 
c The data presented are mean _ S•E. (number of mice). 
d Various amounts of NMMA were injected intraperitoneally at 6 h after 
LPS challenge just prior to injection of the [(MGD) 2/Fe] complex. The 
urine was collected 2 h later. 
* P < 0.05 compared with controls (see Table 1). 
P < 0.05 compared with the LPS-treated group at 6 h. 
Table 3). On the other hand, dexamethasone, an inhibitor 
of the inducible form of • NO synthase, did not show any 
influence on the • NO level produced in the normal mouse 
urine (Fig. 1). However, dexamethasone (3 mg/kg)  also 
did not show any inhibitory effect on the overproduction 
of . NO in the LPS-treated mouse urine (data not shown)• 
This could be due to the lethal levels of LPS used in this 
study to which dexamethasone is no longer effective. 
Our isotopic tracer experiments using JSN-arginine have 
unambiguously demonstrated that the • NO trapped by the 
[(MGD)2/Fe] complex either in normal or the LPS-treated 
mice is produced via arginine-NO pathway (Fig. 2, 3, 4 
and 6). The authenticity of • NO produced in vivo which is 
trapped by the [(MGD)2/Fe] complex in our experimental 
systems is therefore firmly established. Our previous data 
[10] as well as the results presented in this study showed 
clearly that the [(MGD)2/Fe-NO] complex was detected in 
various isolated tissues including the liver and kidneys (for 
example, Fig. 4 of this study). The question is raised on 
whether the [(MGD)2/Fe-NO] complex detected in tissues 
was due to the diffusion of the [(MGD)2/Fe] spin-trapping 
reagent across, for example, the cell membrane of hepato- 
cytes, which then interacts with cellular • NO to produce 
the EPR-active species, or due to the penetration of the 
[(MGD)2/Fe-NO] complex formed elsewhere into hepato- 
cytes. To differentiate these two possible mechanisms, we 
injected intravenously the preformed [(MGD)2/Fe-NO] 
complex into normal mice, and measured EPR-active 
[(MGD)2/Fe-NO] complex in the isolated liver tissue at 
30 min after the injection. No EPR signal of the complex 
in the isolated liver tissue was detected (data not shown), 
indicating that the [(MGD)z/Fe-NO] detected at least in 
the liver tissue was formed resulting from the interaction 
36 A.M. KomaroL,, C.-S. Lai / Biochimica et Biophysica Acta 1272 (1995) 29-36 
of the [(MGD)2/Fe] complex taken up by hepatocytes 
with the intracellular •NO. 
In summary, this ex vivo spin-trapping EPR method can 
be adapted to experiments on larger animals and provides 
a fast, easy and sensitive way of measuring qualitatively 
the constitutive or inducible • NO synthase activities, and 
should be suitable for screening the potential • NO syn- 
thase inhibitors and other pharmaceutical agents that may 
modulate in vivo • NO levels in living animals. Moreover, 
owing to their high in vivo • NO trapping efficiencies and 
relatively low toxicities, the therapeutic efficacy of MGD 
and other related ithiocarbamates for treating pathological 
conditions uch as septic shock, diabetes, allograft rejec- 
tions and cytokine therapies where • NO is overproduced 
merit further investigations. 
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